Source comparison
Intranasal Pharmacokinetics vs Subcutaneous Delivery
Intranasal PT-141 achieves Tmax (time to peak plasma concentration) in 45–60 minutes with Cmax values 30–40% higher than equivalent subcutaneous doses, according to Palatin Technologies' pharmacokinetic studies submitted to the FDA. The mechanism: nasal mucosa
This comparison does not assign a generated winner or score.
- Intranasal PT-141 achieves Tmax (time to peak plasma concentration) in 45–60 minutes with Cmax values 30–40% higher than equivalent subcutaneous doses, according to Palatin Technologies' pharmacokinetic studies submitted to the FDA. The mechanism: nasal mucosa is lined with fenestrated capillaries that allow direct peptide absorption into the superior vena cava, bypassing the hepatic portal system entirely. Subcutaneous injection, by contrast, requires lymphatic uptake and systemic circulation through the liver, where peptidase enzymes degrade 40–60% of the dose before it reaches target tissues.
- Bioavailability comparison from clinical data:
- Intranasal 1.75mg PT-141: 80–85% absolute bioavailability, Tmax 45–60 min, half-life ~2.7 hours
- Subcutaneous 1.0mg PT-141: 40–60% absolute bioavailability, Tmax 90–120 min, half-life ~2.3 hours
- Oral administration: not viable. Peptide bonds hydrolyse completely in gastric acid before absorption
- The intranasal route eliminates injection-site reactions (reported in 8–12% of subcutaneous users) and removes the need for refrigerated storage of pre-filled syringes, which degrade potency by 15–20% per month at ambient temperature. Research-grade intranasal formulations stored at 2–8°C maintain >95% peptide purity for 90 days, confirmed by HPLC analysis.
- What this means for research design: intranasal delivery allows tighter control over dose timing and peak effect windows. If a study requires MC4R activation during a specific behavioural task window, intranasal dosing 45 minutes pre-task achieves peak receptor occupancy. Subcutaneous dosing would require 90–120 minutes lead time with broader variability (±30 minutes) in individual Tmax.